Does estrogen loss after menopause reduce antioxidant defenses and immune regulation?

Context

Menopause is marked by a profound decline in ovarian function and a subsequent drop in circulating estrogen (17β-estradiol) levels. Estrogen is not only a reproductive hormone but also a potent systemic regulator of oxidative stress and immune responses. Its depletion during menopause disrupts the body's homeostatic balance, contributing to the development of chronic, low-grade systemic inflammation and age-related pathologies.

Clinical and Physiological Evidence

• Antioxidant Deficiencies & Oxidative Stress: Clinical and experimental data demonstrate that the loss of estrogen during natural or surgical menopause directly downregulates key cellular antioxidant defenses. Under physiological conditions, estrogen upregulates the transcription and enzymatic activity of vital antioxidant enzymes, particularly superoxide dismutase (including MnSOD and CuZnSOD) and glutathione peroxidase (GPx), through estrogen receptor-dependent signaling. It also maintains adequate levels of reduced glutathione (GSH), a primary cellular antioxidant. Estrogen depletion impairs these pathways, resulting in decreased enzymatic defense, increased reactive oxygen species (ROS) production (often driven by upregulated NADPH oxidase), and elevated systemic oxidative damage (indicated by increased lipid peroxidation and oxidized glutathione). Clinical trials indicate that estrogen-based hormone replacement therapy (HRT) can partially restore these antioxidant enzymes and reduce oxidative stress markers.
• Immune Dysregulation & Inflammatory Cytokines: Estrogen serves as a natural brake on the immune system. With the onset of menopause, the loss of this protective, anti-inflammatory regulation increases vulnerability to inflammatory cytokine activity. Clinical and longitudinal studies in postmenopausal women consistently show elevated systemic concentrations of major pro-inflammatory cytokines, specifically Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin-1 beta (IL-1β). This chronic, low-grade inflammatory state is a key driver behind the increased risk for postmenopausal conditions, including accelerated bone loss (osteoporosis), metabolic dysfunction, and cardiovascular disease.

Molecular Mechanisms

• NF-κB Inhibition and Decay of IκBα: In premenopausal states, estradiol (E2) exerts anti-inflammatory control by inhibiting Nuclear Factor-kappa B (NF-κB), a master transcription factor for pro-inflammatory genes. Estrogen receptors (ERα and ERβ) physically interact with and sequester NF-κB subunits (such as c-Rel and RelA) to prevent their translocation into the nucleus. Additionally, estradiol upregulates and stabilizes IκBα, the primary inhibitor that keeps NF-κB inactive in the cytoplasm.
• Unchecked Cytokine Transcription: When estrogen levels drop during menopause, this molecular brake is lost. Lacking sufficient estrogen, IκBα levels decrease, allowing NF-κB to freely translocate into the nucleus. Once inside, NF-κB binds to the promoters of target genes, directly driving the transcription and release of TNF-α, IL-6, and IL-1β.
• Macrophage Polarization: Estrogen depletion also influences immune cell phenotypes. Adequate estrogen levels promote an anti-inflammatory M2-like macrophage polarization, supporting tissue repair. Estrogen loss shifts the balance toward a pro-inflammatory M1-like state, further escalating the secretion of inflammatory mediators and perpetuating systemic oxidative stress.

                  [ Menopause / Estrogen Loss ]
                                |
         +----------------------+----------------------+
         |                                             |
         ▼                                             ▼
[↓ Antioxidant Defenses]                     [↓ NF-κB Inhibition]
  - ↓ SOD & GPx Enzymes                        - ↓ IκBα expression
  - ↓ Reduced Glutathione (GSH)                - ↑ NF-κB nuclear translocation
         |                                             |
         ▼                                             ▼
   [↑ Cellular ROS]                          [↑ Cytokine Transcription]
   (Oxidative Stress)                        (↑ IL-6, TNF-α, IL-1β)
         |                                             |
         +----------------------++---------------------+
                                ||
                                ▼
              [Chronic Low-Grade Inflammation &]
              [Increased Cellular Vulnerability]

Bottom line

Scientific evidence strongly supports the claim. The loss of estrogen after menopause directly impairs cellular antioxidant defenses (specifically decreasing SOD and GPx activity) and disrupts immune-modulating pathways by removing the inhibitory control on NF-κB. This dual mechanism results in elevated oxidative stress and a pronounced vulnerability to pro-inflammatory cytokines, driving the chronic, low-grade inflammatory state characteristic of the postmenopausal transition.